The role of adjuvant therapy in Stage I ovarian cancer

Hreshchyshyn MM, M M Hreshchyshyn, Park RC, R C Park, J A Blessing, Blessing JA, H J Norris, Norris HJ, D Levy, Levy D, L D Lagasse, Lagasse LD, Creasman WT, W T Creasman
American journal of obstetrics and gynecology · 1980 · vol. 138(2) , pp. 139–45 · doi:10.1016/0002-9378(80)90024-1 · PMID:6252780
RCT OA: closed public-domain-us
View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-31 ⓘ

This randomized trial of Stage I epithelial ovarian carcinoma found that adjuvant chemotherapy significantly reduced recurrence rates compared to no treatment or radiotherapy, suggesting benefit for most patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Women with Stage I epithelial carcinoma of the ovary were initially treated by an extirpative operation and were subsequently randomized to either no further treatment, radiotherapy, or chemotherapy. Only two patients (6%) treated with chemotherapy developed recurrence, compared to five (17%) and seven (30%) patients in the no-treatment and radiotherapy regimens, respectively (P < 0.05). All patients, with the possible exception of those with Stage IA(1)g1, appeared to benefit from adjuvant chemotherapy compared to no treatment or radiotherapy.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma Ovarian Neoplasms Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma, Mucinous Adenocarcinoma, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma Cystadenocarcinoma Cystadenocarcinoma Endometriosis Endometriosis Endometriosis Female Female Humans Humans Neoplasm Recurrence, Local Neoplasm Recurrence, Local

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
pubmed
last seen: 2026-10-08T21:58:08.863946+00:00
unpaywall
last seen: 2026-10-10T06:25:47.132674+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine